Goldenwell Biotech, Inc.
GWLL
$0.20
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7,360.00% | -114.29% | -94.74% | -95.24% | -98.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7,360.00% | -114.29% | -94.74% | -95.24% | -98.90% |
| Cost of Revenue | -125.00% | -100.00% | -100.00% | -80.00% | -98.14% |
| Gross Profit | 37,500.00% | 100.00% | -100.00% | -130.00% | -100.42% |
| SG&A Expenses | -12.74% | 10.07% | 2.23% | -88.26% | -86.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.08% | 9.58% | 1.19% | -88.26% | -87.17% |
| Operating Income | 41.17% | -9.98% | -2.76% | 88.23% | 86.62% |
| Income Before Tax | 34.50% | -17.41% | -12.10% | 87.66% | 86.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 34.50% | -17.41% | -12.10% | 87.66% | 86.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 34.50% | -17.41% | -12.10% | 87.66% | 86.03% |
| EBIT | 41.17% | -9.98% | -2.76% | 88.23% | 86.62% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 35.71% | -8.33% | -8.33% | 86.96% | 84.27% |
| Normalized Basic EPS | 37.50% | -14.29% | -14.29% | 87.72% | 85.45% |
| EPS Diluted | 35.71% | -8.33% | -8.33% | 86.96% | 84.27% |
| Normalized Diluted EPS | 37.50% | -14.29% | -14.29% | 87.72% | 85.45% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.65% | -0.62% | 0.66% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.65% | -0.62% | 0.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |